Advanta Genetics Team Develops COVIDSeq™ as LDT for SARS-CoV-2 Variants of Concern
When classifying and detecting SARS-CoV-2 variants, clinical manifestation of the infection can be dependent on various comorbidities, like age or infecting variant, making treatments variant-specific. But currently there is no FDA approved laboratory test for detecting SARS-CoV-2 variants.
Accordingly, during the pandemic, Advanta Genetics fully validated the Illumina COVIDSeq™ assay as a laboratory developed test in line with CLIA and CAP guidelines. The application was applied throughout the evolution of the pandemic in the East Texas region, and the data was recently published in the journal Archives of Clinical and Biomedical Research.
Link to full article